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comprehensive review of the currently pursued therapeu-
tic strategies, we will discuss what has been achieved by 
immunotherapy and, in particular, how the inherent limita-
tions of this approach can possibly be overcome by novel 
strategies that involve single-chain antibodies.
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Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenera-
tive disease that is characterized by the formation of insolu-
ble protein aggregates as well as the loss of neurons and 
synapses. This causes a progressive decline in memory and 
other cognitive functions that ultimately results in demen-
tia; however, the processes leading to protein aggregation 
and neurodegeneration are only incompletely understood 
[5]. AD was first described in 1907 by Alois Alzheimer 
who reported two pathological hallmarks in the brain: amy-
loid plaques in the extracellular milieu and neurofibrillary 
tangles (NFTs) within neurons. It was not until eight dec-
ades later that the major proteinaceous components of these 
lesions were identified. Amyloid plaques consist primarily 
of aggregates of the amyloid-β peptide (Aβ) [28], whereas 
the main constituent of neurofibrillary tangles is the protein 
tau in a hyperphosphorylated form [34]. To this day, Aβ 
and tau remain the major therapeutic targets for the treat-
ment of AD.
According to the 2010 World Alzheimer Report, it is 
estimated that there are presently 35.6 million people living 
with AD and related disorders, and this figure is expected 
to increase to 115 million by 2050 due to an increasingly 
Abstract Neurofibrillary tangles and amyloid plaques 
constitute the hallmark brain lesions of Alzheimer’s disease 
(AD) patients. Tangles are composed of fibrillar aggregates 
of the microtubule-associated protein tau, and plaques 
comprise fibrillar forms of a proteolytic cleavage product, 
amyloid-β (Aβ). Although plaques and tangles are the end-
stage lesions in AD, small oligomers of Aβ and tau are now 
receiving increased attention as they are shown to correlate 
best with neurotoxicity. One key question of debate, how-
ever, is which of these pathologies appears first and hence 
is upstream in the pathocascade. Studies suggest that there 
is an intense crosstalk between the two molecules and, 
based on work in animal models, there is increasing evi-
dence that Aβ, at least in part, exerts its toxicity via tau, 
with the Src kinase Fyn playing a crucial role in this pro-
cess. In other experimental paradigms, Aβ and tau have 
been found to exert both separate and synergistic modes of 
toxicity. The challenge, however, is to integrate these dif-
ferent scenarios into a coherent picture. Furthermore, the 
ability of therapeutic interventions targeting just one of 
these molecules, to successfully neutralize the toxicity of 
the other, needs to be ascertained to improve current thera-
peutic strategies, such as immunotherapy, for the treatment 
of AD. Although this article is not intended to provide a 
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aged population. As current treatments are purely for mod-
est symptomatic relief, there is an urgent need for an effec-
tive therapeutic for the disease.
The amyloid‑β peptide
Sequential cleavage of the amyloid precursor protein 
(APP) by β- and γ-secretase results in the generation of 
a range of Aβ peptides from 39 to 43 amino acid residues 
in length, although Aβ1–40 and Aβ1–42 are the predominant 
species in vivo. The hydrophobic nature of the peptides, 
particularly Aβ1–42 and Aβ1–43, allows them to self-aggre-
gate and form a myriad of species from dimers to small 
molecular weight oligomers, to protofibrils, to fibrils, 
ultimately leading to their deposition as amyloid plaques 
(Fig. 1). Furthermore, Aβ peptides can also undergo 
pyroglutamate modification at amino acid position three 
(Aβ3(pE)) [63]; this increases the stability, aggregation 
propensity and neurotoxicity compared to full-length, 
unmodified Aβ. Mutations in the genes encoding APP and 
the γ-secretase components, PSEN1 and PSEN2, lead to 
rare, early-onset familial forms of AD (FAD) by increasing 
the overall production of Aβ or shifting γ-secretase cleav-
age to produce more of the amyloidogenic Aβ1–42. The 
mechanism by which excessive Aβ accumulation occurs 
in sporadic AD remains unclear. Reduced Aβ clearance 
or small increases in Aβ production over a long period of 
time are potential mechanisms that result in the accumula-
tion of Aβ in the brain [61].
Fig. 1  Proposed mechanisms underlying the toxic interplay between 
Aβ and tau at the synapse. Aβ oligomers have been demonstrated to 
exert their toxicity at the synapse through a number of mechanisms: 
(1) Binding of Aβ to the plasma membrane forms pores in the mem-
brane, which may be facilitated by lipid rafts, resulting in calcium 
influx into the cell and the downstream activation of kinases impli-
cated in tau phosphorylation. (2) Aβ can mediate the internalization 
of synaptic NMDARs indirectly through the binding of α7 nicotinic 
receptors. This results in a reduction of NMDARs at the synapse 
and causes synaptic spine shrinkage and retraction. (3) Aβ can medi-
ate the activation of extrasynaptic NMDARs, which also induces a 
calcium influx into the neuron and in turn activates kinases such as 
AMPK. Activated kinases can phosphorylate dendritic tau which 
not only causes tau to detach from microtubules and aggregate into 
NFTs, but also enhances its binding to Fyn and results in the migra-
tion of tau and Fyn into the dendritic spine. (4) Within the dendritic 
spine, Fyn phosphorylates NMDARs and thereby mediates their 
interaction with PSD-95—an interaction required for Aβ toxicity. 
(5) Binding of Aβ to PrPc also can activate Fyn to phosphorylate the 
NMDARs. (6) As the disease progresses, Aβ can activate the Fyn 
phosphatase STEP, which inactivates Fyn, resulting in the loss of syn-
apses and dendritic spine collapse
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There is considerable debate regarding which Aβ species 
is the most neurotoxic, with increasing evidence suggesting 
that it is the small molecular weight oligomers that corre-
late best with disease [8, 52, 62, 67]. Consistent with this 
notion, secreted Aβ oligomers and protofibrils have been 
demonstrated to exert their toxicity at the synapse by bind-
ing to the cell surface, disrupting functional receptors and 
causing synaptic dysfunction (Fig. 1). The aggregation of 
Aβ at the cell surface is facilitated by membrane microdo-
mains, termed lipid rafts, which are enriched in cholesterol 
and sphingolipids [37, 46]. Furthermore, the binding and 
disruption of functional receptors such as N-methyl-d-as-
partate receptors (NMDARs) may also be lipid raft depend-
ent [97]. Despite a lack of evidence for a direct binding of 
Aβ to NMDARs, Aβ negatively regulates the number of 
NMDARs at postsynaptic sites, thereby disrupting the bal-
ance between synaptic and extrasynaptic NMDAR activity 
[76]. Exposure of neurons to Aβ oligomers has been dem-
onstrated to enhance NMDAR internalization and decrease 
synaptic expression [92]. This results in a decreased influx 
of Ca2+ into dendritic spines and causes synaptic spine 
shrinkage and retraction [90] (Fig. 1). A direct interac-
tion between Aβ and a number of cell surface receptors, 
including the cellular prion protein (PrPC) [49], the scav-
enger receptor for glycation end products (RAGE) and the 
α7-nicotinergic (α7) receptor, has also been demonstrated 
[103, 104]. Binding of Aβ to the α7 receptor mediates the 
internalization of NMDARs, further shifting the balance 
towards extrasynaptic NMDAR signaling (Fig. 1). Further-
more, binding of fibrillar Aβ oligomers to PrPC activates 
the Src kinase Fyn which increases phosphorylation of the 
NMDAR subunit NR2b, facilitates recruitment of the post-
synaptic density (95 kda) protein (PSD-95), and eventu-
ally results in the loss of surface NMDARs [100] (Fig. 1). 
Recently, Aβ oligomers were also observed to induce 
apoptosis by activating transcription factor 4 (ATF4), 
which is translated and travels back to the cell body to ini-
tiate death signals [4]. It remains unclear, however, how 
the different interactions of Aβ are integrated in causing 
neurodegeneration.
The microtubule‑associated protein tau
Tau is a microtubule-associated protein (MAP) that is 
encoded by the MAPT gene. The protein contains an amino-
terminal projection domain, a proline-rich region, a car-
boxy-terminal domain with microtubule-binding repeats, 
and a short tail sequence. Tau has been reported to interact 
with many proteins, serving important scaffolding func-
tions [16]. In particular, it acts in concert with heterodimers 
of α- and β-tubulin to assemble microtubules and regulate 
motor-driven axonal transport. In the adult human brain, 
tau exists as six isoforms, which have either three or four 
microtubule-binding domains, which result from alterna-
tive splicing of exons two, three and ten of the MAPT gene; 
in contrast, the adult mouse brain only expresses the three 
isoforms with four microtubule-binding domains [57]. Tau 
is enriched in neurons where in mature neurons it is largely 
found in the axon, and is present to a small extent in the 
dendrites. The localization of tau in the dendritic compart-
ments, including the spine, is tightly regulated and has a 
role in targeting Fyn [44].
The distinguishing factor that separates normal tau from 
that observed in patients with AD is its hyperphosphoryla-
tion. The longest isoform of human tau contains 80 serine 
and threonine residues and five tyrosine residues, all of 
which can potentially be phosphorylated. In the disease 
state, tau is hyperphosphorylated to a stoichiometry at least 
three times higher than that in the normal brain, with some 
sites phosphorylated to a higher degree than under physi-
ological conditions and other sites de novo. It is not entirely 
clear, however, whether phosphorylation of tau at specific 
sites results in the pathogenicity observed in AD or whether 
it only requires a certain overall level of phosphorylation, 
as work in fly models would suggest [96]. Nevertheless, 
hyperphosphorylation of tau negatively regulates the bind-
ing of tau to microtubules, as a result of which microtubule 
stabilization and axonal transport are compromised. Hyper-
phosphorylation also increases the capacity of tau to self-
assemble and form aggregates from oligomers to fibrils, 
eventually leading to its deposition as NFTs (Fig. 1). In 
addition, hyperphosphorylated tau has been shown to inter-
fere with neuronal function, causing reduced mitochondrial 
respiration, altered mitochondrial dynamics and impaired 
axonal transport [26]. Tau pathology progresses through 
distinct neural networks and in AD, NFTs are prominent 
early in entorhinal cortex and later appear in anatomically 
connected brain regions [15]. This is thought to occur, in 
part, through the extracellular release of tau and recently 
it was shown that increasing neuronal activity increases 
the steady-state levels of extracellular tau in vivo [107]. 
Furthermore, it has been demonstrated that tau aggre-
gates can have a seeding effect whereby extracellular tau 
can be internalized and upon internalization, these seeds 
can induce the fibrillization of endogenous tau [36]. This 
seeding can be detected prior to detection of tau pathology 
using histopathological markers, suggesting a role for tau 
seeding in neurodegeneration [40].
It is important to note that neurofibrillary lesions are 
also abundant in other neurodegenerative diseases, such as 
Pick’s disease, progressive supranuclear palsy, corticobasal 
degeneration, argyrophilic grain disease, and frontotempo-
ral dementia with parkinsonism linked to chromosome 17 
(FTDP-17), the latter caused by mutations in the MAPT 
gene. These diseases occur in the absence of overt Aβ 
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deposition and demonstrate that tau dysfunction by itself 
can drive neurodegeneration [32].
Synergistic roles of Aβ and tau in AD
Aβ and tau do not act in isolation, rather there is significant 
crosstalk between these two molecules [60, 86, 87]. Inter-
estingly, whereas tau has been placed downstream of Aβ in 
a pathocascade, providing support for the amyloid cascade 
hypothesis [30, 55], a reduction in endogenous tau levels in 
APP transgenic mice was found to reverse memory impair-
ment, reduce susceptibility to experimentally induced 
excitotoxic seizures, and decrease early mortality, without 
altering Aβ levels or plaque load [81]. This evidence of a 
crucial role of tau in synaptotoxicity is supported by the 
observation that hyperphosphorylated tau accumulates in 
dendritic spines of cultured CA3 hippocampal neurons [41, 
112], and the finding that crossing human APP transgenic 
mice with human tau transgenic mice causes an enhanced 
aggregation of tau with concomitant dendritic spine loss, 
and accelerates cognitive impairment [20]. In pyramidal 
neurons of cortical layer V, however, hyperphosphorylated 
tau was not detected in the dendritic spines, even in neurons 
where the somatodendritic compartment was nearly com-
pletely filled with filamentous hyperphosphorylated tau, 
suggesting brain region-specific differences in this localiza-
tion [38]. This difference may be explained by the fact that 
while dendritic spines of cortical pyramidal neurons have 
an actin-based cytoskeleton, the CA3 hippocampal neurons 
occasionally contain microtubules [22, 94].
As previously discussed, under physiological conditions 
tau has a critical role in targeting Fyn to the spine where it 
phosphorylates the NMDAR subunit NR2b, which recruits 
PSD-95 into a protein complex to mediate excitotoxicity. 
In the presence of elevated levels of Aβ (such as in APP 
mutant mice), NMDARs are overactivated, whether by 
direct or indirect binding, causing downstream toxicity. In a 
situation involving elevated levels of both Aβ and phospho-
rylated tau, more Fyn is targeted to the spine, augmenting 
the toxic effects of Aβ [44] (Fig. 1). For example, crossing 
APP mutant mice with transgenic mice carrying the P301L 
tau mutation, which is found in frontotemporal dementia, 
results in 100 % lethality by 4 months of age [43].
The binding of Fyn to tau is mediated by two domains, 
the SH2 domain that binds to tau via phosphorylated Tyr18, 
and the SH3 domain that binds to a series of PXXP motifs 
located in the amino-terminal projection domain of tau 
[50, 51]. Exclusion of Fyn from the dendrite in transgenic 
mice that either express only the amino-terminal projection 
domain of tau (Δtau) or that lack tau completely (tau−/− 
mice) uncouples excitotoxicity in Aβ-depositing mice, 
strongly suggesting a dendritic role of tau in neuronal 
toxicity [44]. As these mice show reduced levels of post-
synaptic Fyn and reduced phosphorylation of its substrate 
NR2b, which facilitates the interaction of NMDARs with 
PSD-95, it is believed that tau stabilizes this complex 
and enhances Aβ-induced toxicity at the synapse through 
NMDARs [44] (Fig. 1). Furthermore, increased intracel-
lular calcium levels induced by Aβ-mediated over-exci-
tation of extrasynaptic NMDARs has been demonstrated 
to activate the kinases AMPK and PAR-1/MARK, which 
in turn induce the phosphorylation of tau. In the presence 
of Aβ oligomers, AMPK has been demonstrated to cause 
phosphorylation of tau at Ser422 [59], an epitope that is 
only phosphorylated late in disease [33] (Fig. 1). As dis-
ease progresses, Aβ has been proposed to activate the Fyn 
phosphatase, striatal-enriched protein tyrosine phosphatase 
(STEP), eventually inactivating Fyn, which leads to the loss 
of synapses and dendritic spine collapse [59, 110] (Fig. 1). 
Together, these findings demonstrate that Aβ may be the 
trigger of AD pathogenesis, and tau may be the bullet [9]. 
From a therapeutic point of view, reducing tau levels or 
preventing the tau/Fyn or NMDAR/PSD-95 interaction is a 
suitable strategy to uncouple excitotoxic downstream sign-
aling. Interestingly, the antiepileptic drug Levetiracetam 
has been shown to reverse synaptic dysfunction, behavioral 
abnormalities, as well as learning and memory deficits in 
APP mutant mice [84]. How Levetiracetam exerts its effect 
is not understood; it has been speculated that it may do so 
through the following causal chain: suppression of aberrant 
network activity, reversal of hippocampal remodeling, and 
recovery of synaptic and cognitive functions. Alternatively, 
Levetiracetam may block glutamate spillover and thereby 
block excitotoxic downstream signaling [84].
Mouse models of AD
AD is a multifactorial disease; the majority of cases are 
sporadic and age is the greatest risk factor, although genetic 
and environmental factors can increase a person’s sus-
ceptibility. Evidently, no mouse model is capable of fully 
recapitulating the neuropathological spectrum of the dis-
ease [72]. Nonetheless, important aspects of AD have been 
reproduced in these models, including its biochemical sig-
natures, histopathological hallmarks, behavioral and motor 
impairments, and, to some degree, neuronal and synaptic 
loss. This has been assisted by the expression of mutations 
that are found in FAD and, as far as tau is concerned, in 
frontotemporal dementia. Interestingly, other than its age 
of onset, FAD cannot be easily discriminated from cases of 
late-onset sporadic AD, and the rationale for using mutant 
transgenic mice has been that, although these mutations are 
rare, they can nonetheless inform our understanding of the 
pathogenic process in the more frequent sporadic forms. 
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In FAD, which accounts for less than 1 % of cases, auto-
somal dominant mutations have been identified in three 
genes, as mentioned above: APP, PSEN1 and PSEN2. The 
majority of FAD cases are caused by mutations in PSEN1 
and PSEN2, and over 130 mutations have been identified. 
Furthermore, more than 20 pathogenic mutations have been 
identified in APP and several of these, including the V717I 
‘London’ mutation [29], the V717F ‘Indiana’ mutation [66], 
the K670D/M671L ‘Swedish’ mutation [65] and the E693G 
‘Arctic’ mutation [69], have been expressed in transgenic 
mice. In these mice, whether they express mutant APP 
alone or are crossed with mutant PSEN mice, elevated Aβ 
levels are observed at an early age, leading to extracellu-
lar amyloid plaque deposition over time; NFTs, however, 
do not form nor do the models exhibit significant neuronal 
loss, which makes them incomplete models of the human 
disease, despite the significant insight they have provided 
into pathogenic mechanisms.
No familial mutations in MAPT have been observed in 
AD; however, mutations have been identified in patients 
with FTDP-17 [31]. Several of the known mutations in 
MAPT have been expressed in transgenic mice, includ-
ing N279 K, ΔK280, P301L, P301S, V337 and R406W, 
which recapitulate tau aggregation, NFT formation and, to 
some degree, neuronal loss. For example, transgenic mice 
expressing P301L mutant tau develop progressive motor 
and behavioral abnormalities, with robust NFT pathology 
and neuronal loss in the spinal cord as early as 6.5 months 
of age [55].
The crosstalk of tau and Aβ was addressed in rats, sev-
eral years before the first transgenic mouse models with 
tau and Aβ pathology became available. Stereotaxic injec-
tions of Aβ into the rat brain induced both a pronounced 
immuno-reactivity for ALZ50, a marker of tau pathology, 
as well as massive neuronal loss [27]. Interestingly, Aβ 
injections led to tau pathology even at distant sites [91]. 
With the identification of pathogenic mutations in the APP 
and MAPT genes in AD and FTDP-17, respectively, mouse 
models with more pronounced pathologies became availa-
ble which were employed to study the interaction of tau and 
Aβ in more detail. When APP mutant mice were crossed 
with P301L tau mutants, the double mutants exhibited a 
substantially enhanced NFT pathology in the limbic sys-
tem and olfactory cortex compared to the single transgenic 
P301L tau mice, despite similar levels of tau expression 
[55]. In contrast, amyloid plaque number, distribution and 
density did not differ between the double transgenic and 
the APP mutant mice. It could be argued that the effects on 
tau elicited by co-expression of mutant APP are, in fact, not 
due to Aβ but rather to APP or other fragments generated in 
the process of proteolytic cleavage of APP. However, using 
a complementary approach and stereotaxically injecting Aβ 
into a second P301L tau transgenic strain, it was clearly 
shown that Aβ is capable of causing increased pathologi-
cal tau phosphorylation and NFT formation [30]. Different 
from the Aβ injections into P301L tau mice, injection into 
wild-type mice failed to induce a tau pathology. In a sub-
sequent study, dilute brain extracts from aged APP mutant 
mice were infused into the hippocampus of young P301L 
tau transgenic mice. Six months later, tau pathology was 
observed not only in the hippocampus but also in brain 
regions to which it is connected, such as the entorhinal cor-
tex and amygdala [12]. Together these findings demonstrate 
that Aβ can accelerate a pre-existing tau pathology in ana-
tomically separated areas, but that the opposite relationship 
cannot be established.
In combining the two pathologies into one mouse model, 
the first triple transgenic model (3xTg-AD) was generated 
by co-expressing mutant forms of PSEN1, APP and tau, 
rather than by crossing independent mouse lines [72]. The 
mice developed extracellular Aβ deposits in the neocortex 
and hippocampus prior to NFT formation, which was first 
apparent in the hippocampus, particularly within pyrami-
dal neurons, and later progressed to involve cortical struc-
tures. The mice also exhibited deficits in synaptic plastic-
ity, including long-term potentiation, which occurred prior 
to extracellular Aβ deposition and the formation of NFTs. 
Interestingly, the deficits in synaptic plasticity correlated 
with intracellular Aβ-immunogenicity, suggesting a role for 
intracellular Aβ in neurotoxicity. Another transgenic strain 
combining mutant APP, PSEN2 and tau (tripleAD) was ana-
lyzed with a particular focus on mitochondrial function, 
based on proteomic data that were obtained in these mice 
showing that one-third of deregulated proteins were mito-
chondrial. The tripleAD mice demonstrated that both Aβ and 
tau act synergistically to induce mitochondrial dysfunction 
and that this was aggravated in aged mice in the presence 
of plaques and tangles [80].
Towards improved models of AD
Most researchers would probably agree that the existing 
transgenic mouse models have contributed significantly 
to our understanding of the pathomechanisms of AD, pro-
viding useful tools for the validation of drug targets, the 
development of treatment strategies and biomarkers, and 
the validation of therapeutic interventions. Yet any model 
has its limitations, including non-human primates, which, 
although they are excellent models for normal aging and 
Aβ neuropathology, lack the tau pathology observed in 
human disease. A species other than mice that is worth 
considering, however, is the degu, a social rodent of South-
American origin, which has a lifespan of 6–8 years and an 
Aβ sequence that is identical to that of humans [42, 101]. 
Unfortunately, the importation of degus can present a 
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hurdle (because they are considered to be a potential pest) 
and holding costs and requirements are significantly higher 
than for mice.
What are the alternatives? In the case of mice, the advent 
of inducible systems has enabled the field to achieve a 
pathology, be it for tau or for Aβ, that is more robust and 
develops faster than with conventional transgenic tech-
niques [85, 102]. A second approach is the use of inducible 
expression systems to achieve brain tissue-specific expres-
sion of tau or Aβ. This has proven particularly useful for 
addressing aspects of the prion-like spreading of pathology 
along neuronal projections. An example of this is the use 
of an entorhinal cortex (EC)-specific promoter to drive tau 
expression alone or with APP expression. In EC-tau mice, 
age-dependent pathology was observed in the EC after sev-
eral months, whereas in EC-tau/APP mice, age-depend-
ent pathology was observed not only in the EC, but also 
in the perirhinal and posterior parietal cortices where the 
promoter conferring EC-specific expression is supposedly 
not active. This suggests that APP acts as an accelerant to 
drive tau toxicity and the spread of pathology observed in 
AD [47].
Finally, with the advent of gene editing methods such 
as TALEN and CRISPR it has become much easier to 
generate knock-in mice and, in particular, to combine sev-
eral mutations ad libitum in one gene [109]. These studies 
should lead to a refinement in the analysis and rapid dissec-
tion of modifiers of tau and Aβ pathology.
AD therapeutic strategies
Previous attempts to treat AD can be broadly classified into 
three categories: general symptomatic treatments, those for 
neuropsychiatric symptoms, and proposed disease-modify-
ing strategies [5]. The first category comprises cholinest-
erase inhibitors and the NMDAR antagonist memantine, 
the second anticonvulsants, antidepressants and atypical 
antipsychotics such as risperidone, and the third ranges 
from natural products such as vitamin E, gingko biloba and 
omega-3 fatty acids, to copper and zinc modulators, β- and 
γ-secretase inhibitors, tau and Aβ aggregation inhibitors 
and, last but not least, immunotherapies. Several theories 
exist for the mechanism of action whereby antibodies can 
clear pathogenic proteins from the brain and reduce the 
deposition of toxic proteins, particularly as many studies 
failed to detect antibodies in the brain. The putative mecha-
nisms that have been put forward include (1) inhibition of 
protein aggregation and ‘seeding’ in the brain, (2) clearance 
via endosomal/lysosomal degradation after internalization 
of antibody complexes, (3) microglial receptor-mediated 
clearance, and (4) establishment of a ‘peripheral sink’ 
whereby removal of a target protein in the periphery would 
decrease brain levels by osmosis (Fig. 2). Although this 
article is not intended to provide a comprehensive review of 
the currently pursued therapeutic strategies, we will discuss 
what has been achieved by immunotherapy and, in particu-
lar, how the inherent limitations of this approach can pos-
sibly be overcome by novel strategies that involve single-
chain antibodies.
Anti-Aβ monoclonal antibodies were first demonstrated 
to dissolve Aβ aggregates in vitro [93] and, since then, both 
active [88] and passive vaccination [6] have been shown 
to prevent plaque deposition, reduce the number of pre-
established plaques and slow cognitive decline in trans-
genic mice expressing APP with the V717F mutation. As 
these transgenic mice do not form NFTs, the ability of 
Aβ-targeted immunotherapeutics to improve cognition in 
the presence of hyperphosphorylated tau, and to reduce the 
progression of other key components of AD neuropathol-
ogy, could not be investigated. However, administration 
of anti-Aβ antibodies into the hippocampus of 3xTg-AD 
mice resulted in a reduction in early tau pathology, which 
occurred after the clearance of Aβ [71, 73]. Furthermore, 
decreasing soluble Aβ without affecting soluble tau levels 
did not improve cognition, suggesting that a reduction in 
both is required to rescue cognitive impairments in this 
mouse model [73]. A 35–40 % reduction in tau hyperphos-
phorylation was also observed in APP Swedish mutant 
mice with a genetic deletion of nitric oxide synthase 2 
(NOS2) after active immunization with Aβ1–42 [105]. In 
P301L tau transgenic mice, however, active immunization 
with Aβ1–42 was not sufficient to prevent the effect of Aβ on 
tau aggregation despite the high serum anti-Aβ titer in this 
model system [48]. Taken together, these studies suggest 
that anti-Aβ immunotherapeutics may be beneficial for the 
treatment of AD but not suffice for the treatment of tauopa-
thies in the absence of advert Aβ pathology.
Despite the encouraging results observed with anti-
Aβ active and passive immunization in animal models of 
AD, the first active vaccination trial of patients with mild-
to-moderate AD, which used a synthetic Aβ1–42 peptide 
together with the adjuvant QS-21 (Elan/Wyeth AN1792), 
was halted when 6 % of immunized patients developed 
aseptic meningoencephalitis and leukoencephalopathy [68, 
74]. Subsequent analysis of the patients that were immu-
nized revealed lower levels of aggregated tau in neuronal 
processes compared to unimmunized AD cases, but not in 
the cell bodies where NFTs reside [10].
The side effects observed after active immunization 
shifted the focus towards passive immunization using 
humanized anti-Aβ monoclonal antibodies, as this was 
perceived to be a safer approach. The first passive anti-
Aβ antibody to be tested in AD was Bapineuzumab, a 
humanized N-terminal specific anti-Aβ antibody. Although 
Bapineuzumab reduced Aβ burden in AD patients in two 
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phase II clinical trials, it recently failed to improve clinical 
outcomes compared to placebo in phase III trials. Among 
patients who carry apolipoprotein E allele ε4 (ApoEε4), 
an allele which increases the risk of developing AD, 
Bapineuzumab was associated with reduced cerebrospinal 
fluid (CSF) phospho-tau concentrations and a decreased 
rate of accumulation of Aβ in the brain [83]. This suggests 
that Bapineuzumab may be beneficial for asymptomatic 
ApoEε4 carriers. Similar to Bapineuzumab, the anti-Aβ 
monoclonal antibody, Solanezumab, which binds to the 
central region of Aβ, also recently failed to show efficacy 
in a phase III clinical trial of patients with mild-to-mod-
erate AD. It did, however, slightly slow the rate of cogni-
tive decline in those with mild AD, although this effect did 
not reach statistical significance. Investigators observed an 
increase in plasma Aβ levels, suggesting a peripheral sink 
mechanism of action; however, an increase in total Aβ lev-
els in the CSF was also observed compared to the placebo-
treated group. This could be accounted for by the stabiliz-
ing effect of the antibody on Aβ as antibody-bound Aβ has 
a significantly prolonged half-life [54, 89]. Additionally, 
there was no significant change in the CSF level of tau or 
phospho-tau in either group [25].
Clinical trials are currently being conducted for the 
next phase of immunotherapies, which have moved away 
from linear Aβ epitopes targeting soluble Aβ to those that 
recognize conformational epitopes on Aβ aggregates; for 
example SAR228810, Gantenerumab [11], BAN2401, 
Aducanumab, ACI-24 [64] and Crenezumab [1] (http:// 
www.clinicaltrials.gov). This reflects a growing awareness 
of the relationship between Aβ oligomers and synaptotox-
icity [79]. One example of this approach is Crenezumab, 
a monoclonal antibody that recognizes multiple forms of 
aggregated Aβ. Recent Phase II data of Crenezumab dem-
onstrated positive trends in cognitive endpoints over time 
in patients with mild to moderate AD but failed to show 
efficacy. Crenezumab is currently being tested in asympto-
matic members of a large Colombian family that has a rare 
PSEN1 mutation, which predisposes them to AD in mid-
dle age. Results from this study will determine if anti-Aβ 
Fig. 2  Proposed mechanisms of action of Alzheimer’s disease immu-
notherapies. AD is characterized pathologically by the aggregation 
of Aβ and tau and their deposition as extracellular amyloid plaques 
and intracellular NFTs, respectively. On their pathway to forming 
plaques and NFTs, Aβ and tau exist as small oligomers that aggre-
gate to fibrils and are the best correlate of neurotoxicity. Prevent-
ing Aβ and tau aggregation and promoting their clearance from the 
brain are the main goals of current immunotherapeutics for the treat-
ment of AD and are depicted in this model. (1) Anti-Aβ antibodies 
that cross the blood–brain barrier (i) bind to aggregated Aβ and aid 
in its disaggregation, (ii) bind to soluble Aβ and prevent further Aβ 
aggregation and/or binding to neurons, and iii activate resident micro-
glia to phagocytose soluble Aβ and help dissolve Aβ plaques. (2) 
Endocytosed antibody–target complexes are cleared via the neuronal 
lysosome. (3) ‘Peripheral sink hypothesis’ whereby the antibody-
mediated depletion of peripheral Aβ and tau causes an efflux of these 
proteins from the brain into the blood. (4) Anti-tau antibodies in the 
brain (i) bind to secreted tau and prevent its ability to ‘seed’ neighbor-
ing neurons or (ii) are endocytosed by neurons and bind to intracellu-
lar tau. Included in this model is a Campbell–Switzer stained amyloid 
plaque from a mutant APP transgenic mouse and a Gallyas silver-
stained NFT within a neuron of a mutant tau transgenic mouse
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immunotherapies are more successful when treatment com-
mences prior to the onset of symptoms.
The high specificity and affinity of antibodies for their 
targets, together with their successful application in the 
treatment and prevention of non-neurodegenerative dis-
eases, suggest that active or passive immunization remains 
a promising therapeutic strategy for AD. As the anti-Aβ 
therapies are failing to meet critical end points in clinical 
trials, however, one cannot rule out the possibility that tau 
might be a more effective therapeutic target. Unfortunately, 
anti-tau immunotherapy studies lag significantly behind 
those for Aβ. This may reflect the belief that an effective 
anti-tau therapeutic would be limited to molecules that 
could cross the plasma membrane. Contrary to this view, 
however, results from studies investigating tau-specific 
active and passive immunization in tau transgenic mice 
have been promising, suggesting a limited level of protec-
tion against tau neurotoxicity despite the possible inability 
of the antibodies to cross the cell membrane.
The initial tau active immunization study, in which wild-
type mice were vaccinated with full-length tau, induced 
the histopathologic features of AD and tauopathies, indi-
cated by the presence of NFTs [82]. However, subsequent 
active immunization studies with peptides containing phos-
phorylation epitopes observed in human disease, such as 
Ser396/404, Ser202/Thr205, Thr212/Ser214, Thr231 and 
Ser422, produced a significant reduction in tau-related 
pathology in tau transgenic mice compared to controls [3, 
7, 14, 98, 99]. Passive immunization with antibodies that 
recognize phosphorylated tau has also shown promising 
results in tau transgenic mice. Immunization with PHF1, 
a monoclonal antibody that recognizes the phosphoryl-
ated residues Ser396/Ser404, resulted in an improvement 
in behavior on the traverse beam task and a reduction in 
tau pathology in the dentate gyrus of the hippocampus in 
tau transgenic mice [13, 21] as well as a significant delay 
in the onset of motor function decline and weight loss in 
the P301S tauopathy model [21]. Plasma levels of PHF1 
reactivity correlated inversely with tau pathology, indicat-
ing that a higher dose of antibodies may have a greater 
therapeutic effect. Similar results were also obtained after 
administration of a conformational antibody, MC1, in the 
same mice [21].
Consistent with the path that studies of anti-Aβ anti-
bodies are taking, the tau field is also focusing on anti-
oligomer antibodies, and antibodies which inhibit tau 
aggregate seeding. TOMA, a tau oligomer-specific mono-
clonal antibody, was injected once either intracerebroven-
tricularly or intravenously into 8-month-old P301L tau 
transgenic mice. Just days after the injections, immunized 
mice exhibited improved cognitive performance and motor 
activity, and a significant reduction in oligomeric tau lev-
els in the brain and spinal cord [18]. In another study, 
anti-tau monoclonal antibodies that had been demonstrated 
to block the seeding activity of P301S tau transgenic brain 
homogenates in vitro were infused into the lateral ventricle 
of P301S mice for 3 months. These antibodies significantly 
reduced hyperphosphorylated, aggregated, and insoluble 
tau, and improved cognitive defects [108]. It is important 
to note that, although some of these antibodies have been 
demonstrated to be internalized by neurons [23, 24, 35], 
many are unable to do so and therefore function by bind-
ing to secreted tau and preventing it from being taken up 
by neighboring neurons [23]. Furthermore, whereas these 
antibodies have shown advantageous effects in tau trans-
genic mice, they have not been tested in transgenic mice 
exhibiting Aβ pathology and it therefore remains uncertain 
whether they will be effective strategies for the treatment 
of AD.
In 2013, phase I clinical trials began to test the effi-
cacy of two active anti-tau vaccines in AD patients. ACI-
35 is a synthetic tau peptide which encompasses the 
Ser396/Ser404 phosphorylation motif [98], whereas AAD-
vac1 targets a truncated, misfolded form of tau [75] and 
consists of a synthetic peptide derived from a tau protein 
sequence, which is coupled to the carrier protein keyhole 
limpet hemocyanin (http://www.clinicaltrials.gov). The 
results from the ongoing human trials are expected later 
this year and are eagerly anticipated.
Future strategies
It has been well demonstrated that Aβ and tau are at the 
heart of AD pathogenesis and their interplay in the disease 
is slowly becoming more evident. Theoretically, based on 
what we know thus far, targeting one of the two molecules 
in AD should reduce the neurotoxicity of the other. Due 
to the complexity of AD and the inability to diagnose and 
treat it early, anti-Aβ immunotherapeutic strategies have 
generated less than desired results. Therapies targeting tau, 
or a combination of both anti-Aβ and anti-tau therapies, 
may be more effective, as it is tau that has been shown to 
drive Aβ synaptotoxicity. To increase the efficacy of tau 
immunotherapeutics one might need to consider enhanc-
ing their cell-penetrating ability, which could be achieved 
through the use of antibody engineering.
Elegant antibody engineering was used to generate a 
bispecific antibody, which targeted the transferrin receptor 
and BACE1. Through binding to the transferrin receptor, 
the bispecific antibody was shown to effectively cross the 
blood–brain barrier and then bind to BACE1 on the neu-
ronal cell surface, thereby reducing Aβ levels in the brain 
[111]. This was mediated through the antibody’s low bind-
ing affinity to the transferrin receptor as it allowed the anti-
body to be released following its entry into the brain and 
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thereby enable it to bind to its secondary target, BACE1. 
Antibody engineering can also be used to generate single-
chain variable antibody fragments (scFvs), which are com-
posed of the variable regions of heavy and light immu-
noglobulin chains joined by a flexible linker; these offer 
the advantage of expression as a single molecule (Fig. 3). 
Although relatively underutilized in the neurodegeneration 
field, scFvs have been extensively used for the diagnosis 
and treatment of different cancers due to their small size 
(25 kDa compared to 150 kDa for a full-length antibody) 
and increased tissue penetration while retaining specificity 
and high affinity for the target protein [2] (Fig. 3). An addi-
tional advantage of scFvs in the context of an AD immuno-
therapeutic is that they lack the effector function region of 
the antibody and are therefore unable to induce the comple-
ment system, which can lead to harmful side effects such 
as microhemorrhages or vasogenic edema [77, 78, 106]. 
Anti-Aβ scFvs have been demonstrated to bind to Aβ with 
nanomolar affinity, inhibit Aβ aggregation, and prevent Aβ-
induced neurotoxicity in vitro [58, 70]. They also reduce 
Aβ plaques and insoluble Aβ levels in the brains of APP 
transgenic mice after chronic intranasal delivery [19] As 
scFvs are single polypeptides they can be further manipu-
lated to include cell-penetrating peptides, allowing the 
scFv to enter the cells to target intracellular proteins [56] 
(Fig. 4). They can also be linked together to form bivalent 
or bispecific diabodies, which exhibit increased stability 
and binding or dual specificity, respectively [39] (Fig. 3).
Gene therapy delivery of anti-Aβ scFvs using adeno-
associated viral (AAV) vectors has demonstrated wide-
spread and long-lasting neuronal delivery and reduced 
Aβ deposition in APP transgenic mice [53]. Furthermore, 
gene therapy delivery of an anti-Huntingtin scFv in a trans-
genic mouse model of Hungington’s disease, using an AAV 
vector that specifically targets neurons, strongly reduced 
neuropathology and improved motor and cognitive defi-
cits compared to control [95] (Fig. 4). Genetic fusion of a 
proteasome-targeting sequence to the scFv was also shown 
to effectively clear scFv-bound target proteins via the pro-
teasomal pathways, thereby reducing neurotoxic proteins 
from the cell [17]. These studies suggest that intracellular 
expression of scFvs (intrabodies) is an effective mechanism 
for targeting neurodegenerative disease-associated proteins 
that are predominantly localized within neurons, with-
out stimulating potentially dangerous side effects such as 
chronic inflammation (Fig. 4).
Lastly, complex diseases, such as HIV, often require the 
use of a combination therapy approach, which may also be 
necessary for the treatment of AD. This was tested recently 
with a phase 1 BACE inhibitor and its phase III anti-
body which, when given together, reduced Aβ levels and 













Fig. 3  Engineered antibody formats. In addition to full-length ‘clas-
sic’ immunoglobulin (IgG) molecules, which are comprised of an 
antigen-binding fragment (Fab) and a crystallisable fragment (Fc), a 
variety of antibody variants are currently being exploited for thera-
peutic intervention. These include: F(ab′)2, which is generated by 
papain digestion of the whole IgG and lacks the Fc region; Fab, 
which comprises only one antigen-binding region; scFv, which is 
composed of the variable heavy and variable light chains of an IgG, 
joined by a flexible linker; bivalent diabodies, which are composed 
of two scFvs which have the same target, joined together by a linker; 
and bispecific diabodies, which are composed of two scFvs with dif-
ferent targets, joined together by a linker
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overexpressing APP, than either treatment did alone [45]. 
Results such as these might be further improved when mul-
tiple proteins, such as Aβ and tau, and multiple neurotoxic 
pathways are concurrently targeted. Existing therapeutics 
for the treatment of other diseases or insults characterized 
by excitotoxicity, such as multiple sclerosis, epilepsy and 
stroke, could also be used in combination with AD-specific 
therapies.
Conclusion
Recent studies have demonstrated a strong interplay 
between soluble Aβ and tau in the AD pathocascade, prior 
to their deposition as plaques and NFTs, respectively, 
with tau acting downstream of Aβ. Consistent with this 
idea, anti-Aβ therapies have demonstrated the ability to 
reduce tau pathology in animal models of disease, and to 
some extent in clinical trials. It is too early to determine 
whether the reverse is true for anti-tau therapies. As we 
continue to learn more about the molecular mechanisms 
underlying the pathogenesis of AD, novel therapeutic 
targets will be identified, which, when targeted as well, 
might enhance the effectiveness of current tau and Aβ 
therapeutics.
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